Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
25 March, 2019 13:37 IST
Lupin receives approval for generic Atovaquone oral solution
Source: IRIS | 13 Sep, 2018, 01.51PM
Comments  |  Post Comment

Lupin, one of the leading pharmaceutical companies in India, announced that it has received approval for its Atovaquone Oral Suspension USP, 750 mg/5 mL from the United States Food and Drug Administration (FDA) to market a generic version of GlaxoSmithKline LLC's Mepron Oral Suspension, 750 mg/5 mL.

Lupin's Atovaquone Oral Suspension USP, 750 mg/5 mL is the generic version of GlaxoSmithKline LLC's Mepron Oral Suspension, 750 mg/5 mL. It is indicated for prevention and acute oral treatment of mild-to-moderate Pneumocystis carinii pneumonia (PCP) in patients intolerant to trimethoprim-sulfamethoxazole (TMP-SMX).

Atovaquone Oral Suspension, 750 mg/5 mL had annual sales of approximately USD 117.4 million in the US (IQVIA MAT June 2018).

Shares of the company settled Rs 16.75 or 1.78% higher at Rs 956.35. (Tuesday).



Lupin Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer